Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.
Barrett’s esophagus
Cancer
Endoscopic resection
Endoscopy
Esophageal adenocarcinoma
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
28
06
2020
accepted:
16
09
2020
pubmed:
30
9
2020
medline:
25
2
2023
entrez:
29
9
2020
Statut:
ppublish
Résumé
Multimodal endoscopic treatment for Barrett's esophagus (BE) related high-grade dysplasia (HGD) and early esophageal adenocarcinoma (EAC) is safe and effective. However, there is a paucity of data to predict the response to endoscopic treatment. This study aimed to identify predictors of failure to achieve complete eradication of neoplasia (CE-N) and complete eradication of intestinal metaplasia (CE-IM). We performed a retrospective analysis of prospectively collected data of all HGD/EAC cases treated endoscopically at a tertiary referral center. Only patients with confirmed HGD/EAC from initial endoscopic mucosal resection (EMR) were included. Potential predictive variables including clinical characteristics, endoscopic features, and index histologic parameters of the EMR specimens were evaluated using multivariate Cox regression. A total of 457 patients were diagnosed with HGD/EAC by initial EMR from January 2008 to January 2019. Of these, 366 patients who underwent subsequent endoscopic treatment with or without RFA were included. Cumulative incidence rates at 3 years for CE-N and CE-IM were 91.4% (95% CI 87.8-94.2%) and 66.8% (95% CI 61.2-72.3%), respectively during a median follow-up period of 35 months. BE segment of 3-10 cm (HR 0.45; 95% CI 0.36-0.57) and > 10 cm (HR 0.25; 95% CI 0.15-0.40) were independent clinical predictors associated with failure to achieve CE-N. With respect to CE-IM, increasing age (HR 0.88; 95% CI 0.78-1.00) was another predictor along with BE segment of 3-10 cm (HR 0.37; 95% CI 0.28-0.49) and > 10 cm (HR 0.15; 95% CI 0.07-0.30). Lymphovascular invasion increased the risk of CE-N and CE-IM failure in EAC cases. Failure to achieve CE-N and CE-IM is associated with long-segment BE and other clinical variables. Patients with these predictors should be considered for a more intensive endoscopic treatment approach at expert centers.
Sections du résumé
BACKGROUND AND AIMS
Multimodal endoscopic treatment for Barrett's esophagus (BE) related high-grade dysplasia (HGD) and early esophageal adenocarcinoma (EAC) is safe and effective. However, there is a paucity of data to predict the response to endoscopic treatment. This study aimed to identify predictors of failure to achieve complete eradication of neoplasia (CE-N) and complete eradication of intestinal metaplasia (CE-IM).
METHODS
We performed a retrospective analysis of prospectively collected data of all HGD/EAC cases treated endoscopically at a tertiary referral center. Only patients with confirmed HGD/EAC from initial endoscopic mucosal resection (EMR) were included. Potential predictive variables including clinical characteristics, endoscopic features, and index histologic parameters of the EMR specimens were evaluated using multivariate Cox regression.
RESULTS
A total of 457 patients were diagnosed with HGD/EAC by initial EMR from January 2008 to January 2019. Of these, 366 patients who underwent subsequent endoscopic treatment with or without RFA were included. Cumulative incidence rates at 3 years for CE-N and CE-IM were 91.4% (95% CI 87.8-94.2%) and 66.8% (95% CI 61.2-72.3%), respectively during a median follow-up period of 35 months. BE segment of 3-10 cm (HR 0.45; 95% CI 0.36-0.57) and > 10 cm (HR 0.25; 95% CI 0.15-0.40) were independent clinical predictors associated with failure to achieve CE-N. With respect to CE-IM, increasing age (HR 0.88; 95% CI 0.78-1.00) was another predictor along with BE segment of 3-10 cm (HR 0.37; 95% CI 0.28-0.49) and > 10 cm (HR 0.15; 95% CI 0.07-0.30). Lymphovascular invasion increased the risk of CE-N and CE-IM failure in EAC cases.
CONCLUSION
Failure to achieve CE-N and CE-IM is associated with long-segment BE and other clinical variables. Patients with these predictors should be considered for a more intensive endoscopic treatment approach at expert centers.
Identifiants
pubmed: 32989547
doi: 10.1007/s00464-020-08037-x
pii: 10.1007/s00464-020-08037-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5468-5479Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
O'Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94(8):2037–2042. https://doi.org/10.1111/j.1572-0241.1999.01275.x
doi: 10.1111/j.1572-0241.1999.01275.x
pubmed: 10445525
Shaheen NJ, Falk GW, Iyer PG, Gerson LB (2016) ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol 111(1):30–50. https://doi.org/10.1038/ajg.2015.322 (quiz 1)
doi: 10.1038/ajg.2015.322
pubmed: 26526079
Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM et al (2017) Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 49(2):191–198. https://doi.org/10.1055/s-0042-122140
doi: 10.1055/s-0042-122140
pubmed: 28122386
Brimhall B, Wani S (2017) Current endoscopic approaches for the treatment of Barrett esophagus. J Clin Gastroenterol 51(1):2–11. https://doi.org/10.1097/mcg.0000000000000742
doi: 10.1097/mcg.0000000000000742
pubmed: 27941583
Phoa KN, Pouw RE, Bisschops R, Pech O, Ragunath K, Weusten BL et al (2016) Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 65(4):555–562. https://doi.org/10.1136/gutjnl-2015-309298
doi: 10.1136/gutjnl-2015-309298
pubmed: 25731874
Desai M, Saligram S, Gupta N, Vennalaganti P, Bansal A, Choudhary A et al (2017) Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc 85(3):482–95.e4. https://doi.org/10.1016/j.gie.2016.09.022
doi: 10.1016/j.gie.2016.09.022
pubmed: 27670227
Belghazi K, van Vilsteren FGI, Weusten B, Meijer SL, Bergman J, Pouw RE (2017) Long-term follow-up results of stepwise radical endoscopic resection for barrett's esophagus with early neoplasia. Gastrointest Endosc. https://doi.org/10.1016/j.gie.2017.04.018
doi: 10.1016/j.gie.2017.04.018
pubmed: 28455160
Bahin FF, Jayanna M, Hourigan LF, Lord RV, Whiteman D, Williams SJ et al (2016) Long-term outcomes of a primary complete endoscopic resection strategy for short-segment Barrett's esophagus with high-grade dysplasia and/or early esophageal adenocarcinoma. Gastrointest Endosc 83(1):68–77. https://doi.org/10.1016/j.gie.2015.04.044
doi: 10.1016/j.gie.2015.04.044
pubmed: 26096759
Chung A, Bourke MJ, Hourigan LF, Lim G, Moss A, Williams SJ et al (2011) Complete Barrett's excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy 43(12):1025–1032. https://doi.org/10.1055/s-0030-1257049
doi: 10.1055/s-0030-1257049
pubmed: 22068701
Gerke H, Siddiqui J, Nasr I, Van Handel DM, Jensen CS (2011) Efficacy and safety of EMR to completely remove Barrett's esophagus: experience in 41 patients. Gastrointest Endosc 74(4):761–771. https://doi.org/10.1016/j.gie.2011.06.009
doi: 10.1016/j.gie.2011.06.009
pubmed: 21824611
Pouw RE, Seewald S, Gondrie JJ, Deprez PH, Piessevaux H, Pohl H et al (2010) Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 59(9):1169–1177. https://doi.org/10.1136/gut.2010.210229
doi: 10.1136/gut.2010.210229
pubmed: 20525701
Krishnamoorthi R, Lewis JT, Krishna M, Crews NJ, Johnson ML, Dierkhising RA et al (2017) Predictors of progression in Barrett's esophagus with low-grade dysplasia: results from a multicenter prospective BE registry. Am J Gastroenterol. https://doi.org/10.1038/ajg.2017.84
doi: 10.1038/ajg.2017.84
pubmed: 28374813
Krishnamoorthi R, Borah B, Heien H, Das A, Chak A, Iyer PG (2016) Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc 84(1):40–6.e7. https://doi.org/10.1016/j.gie.2015.12.036
doi: 10.1016/j.gie.2015.12.036
pubmed: 26772891
pmcid: 4912845
Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR et al (2015) Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett's esophagus. Gastroenterology 149(7):1752–61.e1. https://doi.org/10.1053/j.gastro.2015.08.048
doi: 10.1053/j.gastro.2015.08.048
pubmed: 26327132
Komanduri S, Kahrilas PJ, Krishnan K, McGorisk T, Bidari K, Grande D et al (2017) Recurrence of Barrett's esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol 112(4):556–566. https://doi.org/10.1038/ajg.2017.13
doi: 10.1038/ajg.2017.13
pubmed: 28195178
Thomas T, Ayaru L, Lee EY, Cirocco M, Kandel G, May G et al (2011) Length of Barrett's segment predicts success of extensive endomucosal resection for eradication of Barrett's esophagus with early neoplasia. Surg Endosc 25(11):3627–3635. https://doi.org/10.1007/s00464-011-1769-z
doi: 10.1007/s00464-011-1769-z
pubmed: 21858582
Agoston AT, Strauss AC, Dulai PS, Hagen CE, Muzikansky A, Fudman DI et al (2016) Predictors of treatment failure after radiofrequency ablation for intramucosal adenocarcinoma in barrett esophagus: a multi-institutional retrospective cohort study. Am J Surg Pathol 40(4):554–562. https://doi.org/10.1097/pas.0000000000000566
doi: 10.1097/pas.0000000000000566
pubmed: 26645729
Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y et al (2006) The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 131(5):1392–1399. https://doi.org/10.1053/j.gastro.2006.08.032
doi: 10.1053/j.gastro.2006.08.032
pubmed: 17101315
Stolte M, Kirtil T, Oellig F, Vogel C, Mueller H, May A et al (2010) The pattern of invasion of early carcinomas in Barrett's esophagus is dependent on the depth of infiltration. Pathol Res Pract 206(5):300–304. https://doi.org/10.1016/j.prp.2010.01.005
doi: 10.1016/j.prp.2010.01.005
pubmed: 20188488
Vieth M, Stolte M (2005) Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol 19(6):857–869. https://doi.org/10.1016/j.bpg.2005.02.008
doi: 10.1016/j.bpg.2005.02.008
pubmed: 16338646
Aranda-Hernandez J, Shimamura Y, Grin A, Iwaya Y, Cirocco M, Kandel G et al (2018) Hot avulsion may be effective as salvage treatment for focal Barrett's esophagus remaining after endoscopic therapy for dysplasia or early cancer: a preliminary study. Endoscopy 50(1):8–13. https://doi.org/10.1055/s-0043-119986
doi: 10.1055/s-0043-119986
pubmed: 29065436
Saligram S, Chennat J, Hu H, Davison JM, Fasanella KE, McGrath K (2013) Endotherapy for superficial adenocarcinoma of the esophagus: an American experience. Gastrointest Endosc 77(6):872–876. https://doi.org/10.1016/j.gie.2013.01.014
doi: 10.1016/j.gie.2013.01.014
pubmed: 23472998
Barret M, Belghazi K, Weusten BL, Bergman JJ, Pouw RE (2016) Single-session endoscopic resection and focal radiofrequency ablation for short-segment Barrett's esophagus with early neoplasia. Gastrointest Endosc 84(1):29–36. https://doi.org/10.1016/j.gie.2015.12.034
doi: 10.1016/j.gie.2015.12.034
pubmed: 26769410
Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M et al (2013) Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 145(1):96–104. https://doi.org/10.1053/j.gastro.2013.03.046
doi: 10.1053/j.gastro.2013.03.046
pubmed: 23542068
Li N, Pasricha S, Bulsiewicz WJ, Pruitt RE, Komanduri S, Wolfsen HC et al (2016) Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett's esophagus: results from the United States Radiofrequency Ablation Registry. Dis Esophagus 29(6):537–543. https://doi.org/10.1111/dote.12386
doi: 10.1111/dote.12386
pubmed: 26121935
Luckett T, Allamneni C, Cowley K, Eick J, Gullick A, Peter S (2018) Length of Barrett's segment predicts failure of eradication in radiofrequency ablation for Barrett's esophagus: a retrospective cohort study. BMC Gastroenterol 18(1):67. https://doi.org/10.1186/s12876-018-0799-6
doi: 10.1186/s12876-018-0799-6
pubmed: 29783927
pmcid: 5963157
Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S (2012) Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 143(3):576–581. https://doi.org/10.1053/j.gastro.2012.05.005
doi: 10.1053/j.gastro.2012.05.005
pubmed: 22609385
Iwaya Y, Shimamura Y, Mosko JD, Kandel G, Kortan PP, May GR, Marcon NE, Teshima CW (2019) Clinical characteristics may distinguish patients with esophageal adenocarcinoma arising from long-versus short-segment Barrett’s esophagus. Dig Liver Dis 51(10):1470–1474. https://doi.org/10.1016/j.dld.2019.05.009
Sharma P, Bergman JJ, Goda K, Kato M, Messmann H, Alsop BR et al (2016) Development and validation of a classification system to identify high-grade dysplasia and esophageal adenocarcinoma in barrett's esophagus using narrow-band imaging. Gastroenterology 150(3):591–598. https://doi.org/10.1053/j.gastro.2015.11.037
doi: 10.1053/j.gastro.2015.11.037
pubmed: 26627609
Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV (2014) Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2008). Dis Esophagus 27(8):757–763. https://doi.org/10.1111/dote.12147
doi: 10.1111/dote.12147
pubmed: 24118313
Kambhampati S, Tieu AH, Luber B, Wang H, Meltzer SJ (2020) Risk factors for progression of Barrett's esophagus to high grade dysplasia and esophageal adenocarcinoma. Sci Rep 10(1):4899. https://doi.org/10.1038/s41598-020-61874-7
doi: 10.1038/s41598-020-61874-7
pubmed: 32184470
pmcid: 7078316
Alnasser S, Agnihotram R, Martel M, Mayrand S, Franco E, Ferri L (2019) Predictors of dysplastic and neoplastic progression of Barrett’s esophagus. Can J Surg 62(2):93–99. https://doi.org/10.1503/cjs.008716
doi: 10.1503/cjs.008716
pubmed: 30907564
pmcid: 6440887
Krishnamoorthi R, Singh S, Ragunathan K, Visrodia K, Wang KK, Katzka DA et al (2018) Factors associated with progression of Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 16(7):1046–55.e8. https://doi.org/10.1016/j.cgh.2017.11.044
doi: 10.1016/j.cgh.2017.11.044
pubmed: 29199147
Krishnamoorthi R, Singh S, Ragunathan K et al (2016) Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. Gastrointest Endosc. 83(6):1090.e3–1106.e3. https://doi.org/10.1016/j.gie.2016.02.009
doi: 10.1016/j.gie.2016.02.009
Lee J, Anggiansah A, Anggiansah R, Young A, Wong T, Fox M (2007) Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol 5(12):1392–1398. https://doi.org/10.1016/j.cgh.2007.08.011
doi: 10.1016/j.cgh.2007.08.011
pubmed: 17936081
Otaki F, Ma GK, Krigel A, Dierkhising RA, Lewis JT, Blevins CH et al (2020) Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Gastrointest Endosc. https://doi.org/10.1016/j.gie.2020.01.013
doi: 10.1016/j.gie.2020.01.013
pubmed: 32586549
pmcid: 7321863